top of page
Because market access strategies should be rooted in the truth, not conjecture
We allow biopharma to ask the right people the right questions at the right time
We created Formulary Insights to help biopharmaceutical investors, marketers, and leaders better understand and anticipate payer and specialty pharmacy perceptions of every therapeutic area.
WHAT WE DO
We only provide you with insights from
real decision makers
No retirees,
no loose affiliations,
no misrepresentations
OUR UNIQUE VALUE PROPOSITION
OUR PANEL
Only FORMULARY INSIGHTS can identify active market access decision makers
OUR SPEED
Actionable insights in weeks not months
OUR PEOPLE
Insights interpreted only by those who’ve been there before
May 14, 2020 | John Fox and Mark O'Neill
Payers have transformed the competitive marketplace, and biopharma companies need to regain their position as the authority on their products. To do this, they must establish new ways to anticipate, identify, and react to payer impressions of relevant evidence as they occur.
NO RETIREES, NO LOOSE AFFILIATIONS, NO MISREPRESENTATIONS
All our panelists are active decision makers
Do you want to see a sample of our research?
Customized samples available upon request.
OUR MOST POPULAR OFFERINGS
FIRST
The answers you need. From the payers you want. In time to act.
DIRECT INQUIRY
Your opportunity for exhaustive research on key areas of interest
A single-study deep-dive to ensure a complete understanding of payer interests and impressions
SYNDICATED RESEARCH
All the benefits of our Direct Inquiry studies without the compliance requirements of developing your own
TESTIMONIALS
Pre-launch Study Evaluations gave us the insights that informed Phase 3 study design in time for us to include critical payer endpoints.
With a second indication on the horizon, a therapeutic class Drug Monograph Analysis revealed several unexpected perspectives that we leveraged to protect access.
Pre-launch competitive Label Comparison enabled us to prioritize our label negotiations to ensure our payer value was well represented at launch.
When we launched our small KAM team, we targeted Hospital System panelists to garner system-specific product insights that drove segmentation and prioritization of KAM targeting.
We bought a Rapid Study subscription so that we can put out fires quickly based on feedback from our panelists whenever we need it!
A Formulary Insights Direct Inquiry provided us with the payer insights we needed to make a go or no-go decision on several planned product strategies based on their expected access impact, quickly enhancing our product access and performance.
CONTACT US
There finally is a better way.
Get REAL insights from ACTIVE formulary decision makers in time to act.
We are ready to go to work for you today.
Imagine a room where America’s most sought-after market access decision makers have gathered for all your questions
We allow biopharma to ask the right people the right questions at the right time
bottom of page